辰欣药业股份有限公司 关于2025年第三季度业绩说明会召开情况的公告

Group 1 - The company held its Q3 2025 earnings presentation on November 26, 2025, via an online interactive format, addressing investor concerns [2][3] - The company reported a decline in revenue for the first three quarters of 2025, but the decrease in net profit attributable to shareholders was smaller due to effective cost control and increased investment income [3][4] - The company plans to enhance its core business profitability by improving innovation capabilities and expanding its product supply chain services [3] Group 2 - The company has improved its operating cash flow significantly but acknowledged potential risks related to accounts receivable, implementing measures to strengthen collection management [4] - The company has multiple products that have won bids in the national drug procurement program, which presents both opportunities and challenges, as lower drug prices may be offset by increased sales volume [5][6] - The company is focusing on its overseas business as a key growth area, which has gradually become a significant contributor to its performance [7] Group 3 - The major shareholder, Han Yanzhen, reduced his stake in the company from 7.06% to 4.999% through a combination of block trades and open market transactions, totaling 10,708,500 shares [26][28] - The reduction in shareholding does not trigger a mandatory takeover bid, and the company's control structure remains unchanged [29][30]